title: Chemotherapy-related polyneuropathy may deteriorate quality of life in patients with B-cell lymphoma.
abstract: OBJECTIVE
  This prospective study was performed to evaluate the effect of chemotherapy-related neurotoxicity on quality of life (QOL) of patients with lymphoma.
  
  
  METHODS
  Thirty-two patients with diffuse large B-cell or follicular lymphoma without prior evidence of neuropathy were enrolled. Patients underwent the evaluations based on neuropathy symptom and disability score, nerve conduction studies, and SF-36 questionnaire for QOL assessment. They received six cycles of chemotherapy every three weeks, and all evaluations were repeated during and after the completion of 6th cycle.
  
  
  RESULTS
  Sensory neuropathy-associated symptoms were observed in 27 patients (84.4%), and polyneuropathy was confirmed by nerve conduction study in 14 patients (43.8%). These patients with polyneuropathy showed worse QOL in domains mainly associated with physical health status including "physical function" compared to patients without polyneuropathy. There was a significant association of neuropathy symptom and disability scores with "bodily pain" and "vitality" of QOL domains. The serial evaluations of patients with neuropathy showed a worsening of QOL and neuropathy symptom scores during chemotherapy, then improvement of these values after chemotherapy. Thus, the final nerve conduction study confirmed the decrease in polyneuropathy compared to the 2nd evaluation (P = 0.032).
  
  
  CONCLUSIONS
  Chemotherapy-related polyneuropathy may deteriorate QOL of patients with lymphoma, mainly physical health-associated QOL.
authors.affiliation: Department of Neurology, Korea University College of Medicine, Seoul, Korea.
authors.forename: Byung-Jo
authors.initials: BJ
authors.lastname: Kim
authors.forename: Ha-Rim
authors.initials: HR
authors.lastname: Park
authors.forename: Hak Jae
authors.initials: HJ
authors.lastname: Roh
authors.forename: Du-Shin
authors.initials: DS
authors.lastname: Jeong
authors.forename: Byung Soo
authors.initials: BS
authors.lastname: Kim
authors.forename: Kun-Woo
authors.initials: KW
authors.lastname: Park
authors.forename: S Charles
authors.initials: SC
authors.lastname: Cho
authors.forename: Yuen T
authors.initials: YT
authors.lastname: So
authors.forename: Sung Yong
authors.initials: SY
authors.lastname: Oh
authors.forename: Seok Jin
authors.initials: SJ
authors.lastname: Kim
mesh_terms: D000328:Adult; D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006304:Health Status; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy*; D008224:Lymphoma, Follicular / Q000188:drug therapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011115:Polyneuropathies / Q000139:chemically induced* / Q000150:complications* / Q000503:physiopathology; D011239:Prednisolone / Q000008:administration & dosage; D011446:Prospective Studies; D011788:Quality of Life; D000069283:Rituximab; D012720:Severity of Illness Index; D014750:Vincristine / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone